Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low Grade Ovarian Serous Adenocarcinoma”

16 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 16 of 16 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225
Large-scale testing (Phase 3)Looking for participantsNCT05601700
What this trial is testing

Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial)

Who this might be right for
Carcinoma, Ovarian EpithelialLow Grade Serous Adenocarcinoma of Ovary
Ente Ospedaliero Ospedali Galliera 132
Early research (Phase 1)Looking for participantsNCT05950464
What this trial is testing

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

Who this might be right for
Recurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid Adenocarcinoma+6 more
National Cancer Institute (NCI) 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT03531645
What this trial is testing

Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

Who this might be right for
Malignant Neoplasms of Female Genital Organs
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT00551070
What this trial is testing

Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer

Who this might be right for
Borderline Ovarian Serous TumorLow Grade Ovarian Serous AdenocarcinomaMicropapillary Serous Carcinoma+3 more
National Cancer Institute (NCI) 52
Large-scale testing (Phase 3)Active Not RecruitingNCT04095364
What this trial is testing

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Who this might be right for
Low Grade Fallopian Tube Serous AdenocarcinomaOvarian Low Grade Serous AdenocarcinomaPrimary Peritoneal Low Grade Serous Adenocarcinoma+9 more
NRG Oncology 450
Not applicableLooking for participantsNCT00488878
What this trial is testing

Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaMalignant Ovarian NeoplasmOvarian Carcinoma+3 more
M.D. Anderson Cancer Center 2,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04575961
What this trial is testing

Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer

Who this might be right for
Ovarian CancerLow Grade Serous CarcinomaPrimary Peritoneal Carcinoma+1 more
North Eastern German Society of Gynaecological Oncology 33
Testing effectiveness (Phase 2)Active Not RecruitingNCT04739800
What this trial is testing

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Who this might be right for
Fallopian Tube Mucinous AdenocarcinomaOvarian Seromucinous CarcinomaPlatinum-Refractory Fallopian Tube Carcinoma+47 more
National Cancer Institute (NCI) 120
Testing effectiveness (Phase 2)Looking for participantsNCT06494150
What this trial is testing

Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)

Who this might be right for
Low Grade Ovarian Serous Adenocarcinoma
University of Oklahoma 37
Large-scale testing (Phase 3)Study completedNCT02101788
What this trial is testing

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Who this might be right for
Borderline Ovarian Serous TumorMicropapillary Serous CarcinomaOvarian Serous Adenocarcinoma+3 more
National Cancer Institute (NCI) 260
Early research (Phase 1)Active Not RecruitingNCT04092270
What this trial is testing

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

Who this might be right for
Endometrial High Grade Endometrioid AdenocarcinomaFallopian Tube Clear Cell AdenocarcinomaFallopian Tube Endometrioid Adenocarcinoma+26 more
National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT02834013
What this trial is testing

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Who this might be right for
Acinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma+91 more
National Cancer Institute (NCI) 818
Early research (Phase 1)UnknownNCT03875820
What this trial is testing

Phase I Trial of Defactinib and VS-6766.

Who this might be right for
NSCLCLow Grade Serous Ovarian CancerEndometrioid Carcinoma+1 more
Institute of Cancer Research, United Kingdom 87
Testing effectiveness (Phase 2)Active Not RecruitingNCT03673124
What this trial is testing

Ribociclib and Letrozole Treatment in Ovarian Cancer

Who this might be right for
Low Grade Serous Carcinoma
Gynecologic Oncology Group 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT05554367
What this trial is testing

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Who this might be right for
Exocrine Pancreas CarcinomaMalignant Solid NeoplasmOvarian Low Grade Serous Adenocarcinoma+2 more
National Cancer Institute (NCI) 199